Advertisement

Topics

Jnana Therapeutics Inc. Company Profile

09:46 EST 16th November 2018 | BioPortfolio

Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier (SLC) family of metabolite transporters as a therapeutic target class. Jnana is systematically targeting SLCs, the cell’s metabolic gates, to advance first-in-class therapies for diseases where patients have limited or no treatment options. Headquartered in Boston, Jnana launched in 2017 with $50 million in Series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com, and follow us on Twitter and on LinkedIn.


News Articles [717 Associated News Articles listed on BioPortfolio]

Jnana Therapeutics Appoints Joanne Kotz to Chief Executive Post

Joanne Kotz has been named CEO of Jnana Therapeutics. Kotz, a co-founder of Jnana, had been president of the company since last December, when it raised $50 million in Series A financing. Jnana is res...

Neurocrine Biosciences, Jnana Therapeutics to discover medicines for CNS disorders

The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CN...

Jnana, Neurocrine enter discovery pact for small-molecule CNS disorder therapeutics

Jnana Therapeutics Inc. and Neurocrine Biosciences Inc. are allying to discover multiple targets from which to develop small-molecule therapeutics for CNS disorders.

Jnana Therapeutics Announces Appointment of Joanne Kotz, Ph.D. as Chief Executive Officer

Jnana Therapeutics today announced that Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana’s president since December...

FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018

Jnana Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising privat...

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, which will be headquartered in Japan and known as MAGiQ Therapeutics Inc. R...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...

PubMed Articles [469 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [162 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1271 Associated Companies listed on BioPortfolio]

Jnana Therapeutics Inc.

Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier (SLC) family of metabolite transporters as a therapeutic targ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Jnana Therapeutics Inc." on BioPortfolio

We have published hundreds of Jnana Therapeutics Inc. news stories on BioPortfolio along with dozens of Jnana Therapeutics Inc. Clinical Trials and PubMed Articles about Jnana Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Jnana Therapeutics Inc. Companies in our database. You can also find out about relevant Jnana Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record